Clinical trial
A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
NCT01004432 is registered in ClinicalTrials.gov with Janssen Biotech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
- Lead sponsor
- Janssen Biotech, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2009
- Completion date
- October 31, 2013
- Enrollment
- 433 (actual)
- Sites
- 117
Conditions
As the registry lists them; a condition with its own page is linked.